The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics (2nd Edition): Distribution by Type of Protein degrader (degronimids, PROTACs, SARDs / SERDs, specific BET, DUB and other inhibitors), Therapeutic Areas (Neurological Disorders, Oncological Disorders and Others), Route of administration (Oral, Intravenous and Others), Key Contributing Technologies and Key Geographies (North America, Europe, Asia-Pacific, Latin America, MENA, and Rest of the World), 2021-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    March 2021

  • Pages
    434

  • View Count
    17414

Example Insights

Targeted-Protein-Degradation-Market-Context Targeted-Protein-Degradation-Market-Pipeline Targeted-Protein-Degradation-Market-Distribution-by-Therapeutic-Area Targeted-Protein-Degradation-Market-Developer-Landscape Targeted-Protein-Degradation-Market-Distribution-by-Company-Size
Targeted-Protein-Degradation-Market-Patent-Analysis Targeted-Protein-Degradation-Market-Grant-Analysis Targeted-Protein-Degradation-Market-Funding-and-Investments Targeted-Protein-Degradation-Market-Clinical-Trial-Analysis Targeted-Protein-Degradation-Market-Mapping-Key-Opinion-Leaders
Targeted-Protein-Degradation-Market-Partnerships-and-Collaborations Targeted-Protein-Degradation-Market-Deal-Structures Targeted-Protein-Degradation-Market-Opportunity-Analysis Targeted-Protein-Degradation-Market-Forecast  

 

Overview

Targeted protein degradation is a revolutionary pharmacological concept that presents viable drug development opportunities and is anticipated to introduce a new paradigm in modern therapeutic interventions. Due to various reasons, conventional drugs / therapies have been limited in terms of their capability to target certain proteins of pathological significance. Presently, medical researchers engaged in the development of bifunctional protein degrader-based interventions claim that this upcoming class of drugs is capable of targeting biomolecules in the human proteome, which were previously considered undruggable. The concept of targeted protein degradation revolves around the use of small molecule leads, which are capable of recruiting the ubiquitin-proteasome system (UPS) to selectively eliminate a target biomolecule. In other words, protein degraders regulate biological pathways by selectively downregulating a target protein by degrading them; this process has been shown to be robust, more sensitive to drug-resistant targets and can regulate cellular functions that are not dependent on enzyme action. Moreover, drugs designed based on this relatively novel concept, have been shown to demonstrate a remarkable level of selectivity, high potency, oral bioavailability and differentiated pharmacology, compared to traditional enzyme inhibitors. As a result, this upcoming class of drugs has garnered significant interest within the medical science community. In fact, the growing popularity of targeted protein degradation is evident in the USD 5 billion in capital investments made into companies engaged in this field of research, since 2014.

Proteolysis targeting chimera (PROTAC), developed by Hashimoto Laboratory in 2008, was the first targeted protein degrader. The incessant efforts of researchers involved in this domain have resulted in significant progress towards understanding the physiochemical and biological properties of such bifunctional molecules. Presently, there are several other types of targeted protein degraders and molecular glues, which have been / are being developed for the treatment of a variety of clinical conditions, including acute myeloid leukemia, Alzheimer's disease, breast cancer, myelofibrosis, multiple myeloma, Parkinson's disease, prostate cancer, psoriasis, rheumatoid arthritis, and supranuclear palsy. It is worth noting that the R&D efforts in this field are supported by DNA-encoded libraries and other in silico hit discovery and characterization tools. In the last 4-5 years, there has been a marked rise in the number of new entrants in this market. Additionally, several big pharma players are also actively involved in this field, evaluating proprietary protein degrader-based therapeutic leads. The market has also witnessed substantial partnership activity over the last few years, with several technology developers involved in high-value licensing deals. Although, there are no approved protein degrader-based drugs / therapy products, the market is poised to witness healthy growth over the next decade.

Scope of the Report

The ‘Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics (2nd Edition), 2021-2030: Distribution by Type of Protein degrader (degronimids, PROTACs, SARDs / SERDs, and specific BET and DUB inhibitors, and other inhibitors), Therapeutic Area (Neurological Disorders, Oncological Disorders, and Other Therapeutic Areas), Route of administration (Oral, Intravenous and Others), Key Contributing Technologies and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World)’ report features an extensive study of the current and future potential of protein degraders, offering an informed opinion on the likely adoption of these therapeutics and affiliated technologies, over the next decade. The focus of this study is on specially designed small molecule degraders, including degronimids, endosome targeting chimeras (ENDTACs), epichaperome inhibitors, hydrophobic tags, immuno-modulatory imide drugs (IMiDs), lysosome targeting chimeras (LYTACs), molecular glues, photochemically targeting chimeras (PHOTACs), proteolysis targeting chimeras (PROTACs), protein homeostatic modulators, selective androgen receptor degraders (SARDs), selective estrogen receptor degraders (SERDs), specific and non-genetic IAP-dependent protein erasers (SNIPERs), and specific bromodomain and extra-terminal motif (BET) inhibitors and deubiquitinase (DUB) inhibitors. In addition, the report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.  Amongst other elements, the report includes:

  • A detailed review of the current market landscape of targeted protein degradation-based therapeutics, including information on type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key therapeutic area(s), type of biological target(s), associated ubiquitin ligase(s) (if available), target signaling pathway (if available), mechanism of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others). In addition, it presents a list on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), clinical study sponsor(s) and collaborator(s). 
  • An overview of the overall landscape of target protein degradation enabling technologies, featuring an analysis based on type of degrader. In addition, it presents a list of targeted protein degradation enabling technology developers and analysis based on various parameters, such as year of establishment, company size and location of headquarters. 
  • Detailed profiles of prominent players engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products). Each profile features a brief overview of the company, its financial information (if available), detailed description of their respective lead drug candidates, and recent developments and an informed future outlook. Additionally, each drug profile features information on the type of drug, current status of development, route of administration, target indications, and a brief summary of its developmental history. 
  • Tabulated profiles of leading industry players (shortlisted on the basis of the number of candidates in development pipeline). Each profile includes details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with information on respective drug candidates. 
  • An in-depth analysis of completed, ongoing and planned studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), trial focus, target therapeutic area, key indications, and clinical endpoints.
  • A detailed analysis of grants that have been awarded to various research institutes for targeted protein degradation projects, in the period between 2017 and 2020, on the basis of important parameters, such as year of award, amount awarded, administering institute center, support period, funding mechanism, type of grant application, purpose of grant award, activity code, emerging focus areas of the grants, study section, popular NIH departments, study section, and type of recipient organization, highlighting popular recipient organizations, popular program officers and regional distribution of recipient organizations.  
  • A detailed publication analysis peer-reviewed, scientific articles that have been published between 2017 and Q3 2019, highlighting the research focus within the industry. It also highlights the key trends observed across publications, including information on type of publication, year of publication, study objective, popular keywords, type of protein degrader, biological target, associated ubiquitin enzyme, number of publications, type of publisher, leading players (in terms of number of publications), region, and key journals (in terms of number of articles published in this domain and impact factor of the journal). 
  • An insightful analysis of the patents filed / granted for targeted protein degradation enabling technologies, since 2018, taking into consideration various parameters, such as type of patent, publication year, geographical location, type of applicant, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. The chapter also includes a detailed patent benchmarking and an insightful valuation analysis.
  • A list of key opinion leaders (KOLs) within this domain, and their assessment (based on the strength and activeness) represented in the form of 2×2 matrices. The chapter also includes a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).
  • An analysis of the partnerships that have been established in this domain, during the period 2014-2020, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.
  • An analysis of the investments in the form of seed financing, venture capital financing, debt financing, grants / awards, initial public offerings (IPOs) and subsequent offerings, made at various stages of development of the companies engaged in this field.
  • A detailed deal structure analysis, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities of novel technologies for the development of targeted protein degraders. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided informed estimates on the evolution of the market over the period 2021-2030. For estimating the future market opportunities for technology providers, we have considered the likely licensing deal structures and agreements that are likely to be established in the foreseen future. The future opportunity within the targeted protein degradation market has been segmented across [A] different types of protein degraders (degronimids, PROTACs, SARDs / SERDs, Specific BET and DUB Inhibitors, and other inhibitors), [B] therapeutic areas (oncological disorders, neurological disorders, and other therapeutic areas), [C] route of administration (oral route, intravenous route, and other routes), and [D] key geographical regions (North America, Europe and Asia Pacific). In order to account for future uncertainties associated with the growth of targeted protein degradation market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):

  • Laura Itzhaki, Founder and Chief Scientific Officer, Polyprox Therapeutics
  • Louise Bergeron, Vice President, Xios Therapeutics
  • Martin Wiles, Vice President Business Development and Licensing, Almac Discovery & Gerald Gavory, Director of Biology, Almac Discovery
  • Jason Brown, Scientific and Business Development Director, Ubiquigent
  • Anonymous, Director of Oncology Research, Large Company
  • Anonymous, Chief Scientific Officer, Very Small Company
  • Paul Wallace, Chief Business Officer, Mission Therapeutics
  • Katrin Rittinger, Research Group Leader, Francis Crick Institute
  • Zhihao Zhuang, Associate Professor, Department of Chemistry and Biochemistry, University of Delaware

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry and non-industry players engaged in this market?
  • What are the key therapeutic areas for which target protein degraders are being / have been developed?
  • Which geographies are the most active in conducting clinical trials on target protein degraders?
  • What kind of partnership models are commonly adopted by industry stakeholders? 
  • Which are the leading administering institute centers supporting the research related to this domain?
  • What is the trend of capital investments in the targeted protein degradation market?
  • How has the intellectual property landscape in this market evolved over the years?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of targeted protein degradation-based drugs market and its likely evolution in the short-mid- term and long term.

Chapter 3 provides an introduction to protein homeostasis, including a discussion on the UPS for intracellular protein degradation and turnover. It presents an elaborate discussion on the structure and function of ubiquitin, various components of the UPS and key steps involved in the UPS-based protein degradation. Further, the chapter provides an overview of the concept of targeted protein degradation, including details on various protein degraders and their associated pathways and mechanisms of action. The chapter also includes a discussion on the historical evolution, importance, advantages and challenges associated with the use of targeted protein degradation as a therapeutic principle. In addition, the chapter describes the key growth drivers and roadblocks related to targeted protein degraders, offering insights on the upcoming trends in the domain.

Chapter 4 includes information on more than 155 targeted protein degraders that are currently being evaluated in different stages of development (both clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules, based on their types of protein degraders (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indications, key therapeutic areas, types of target proteins, target enzymes (if available), target signaling pathways (if available), mechanisms of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any). Further, the chapter provides information on drug developer(s), highlighting their year of establishment, location of headquarters and company size. 

Chapter 5 provides an overview of the overall landscape of the targeted protein degradation enabling technologies, including an analysis based on type of degrader. In addition, the chapter features a list of technology developers and an analysis based on several parameters, such as such as year of establishment, company size, and location of headquarters.

Chapter 6 features elaborate profiles of prominent players engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products). Each company profile includes a brief overview of the company, its financial information (if available), details on their respective lead drug candidates, recent development and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history. Further, the chapter includes tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the developer (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates.

Chapter 7 provides a detailed analysis of completed, ongoing and planned clinical studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.

Chapter 8 provides an analysis of more than 770 grants that were awarded to research institutes engaged in target protein degradation, in the period between 2017 and 2020 based on the important parameters, such as year of award, amount awarded, administering institute center, support period, funding mechanism, type of grant application, purpose of grant award, activity code, emerging focus areas of the grants, study section, popular NIH departments, study section, type of recipient organizations, popular recipient organizations, popular program officers and regional distribution.

Chapter 9 provides information on certain recent publications that we came across during our research on target protein degradation. This chapter highlights the key trends observed across publications, including information on type of publication, year of publication, study objective, popular keywords, type of protein degrader, biological target, associated ubiquitin enzyme, number of publications, type of publisher, leading players (in terms of number of publications), region, and key journals (in terms of number of articles published in this domain and impact factor of the journal). 

Chapter 10 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed / granted related to target protein degradation, since 2018, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.

Chapter 11 provides an analysis of KOLs in the field of targeted protein degradation. It features a comprehensive list of principal investigators / study directors of different clinical trials, along with information related to the affiliated research institutes. The chapter features a schematic representation of a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The (relative) level of expertise of different KOLs defined by other analysts / industry experts were compared to the results obtained using a proprietary scoring criterion, which was based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).

Chapter 12 features an elaborate discussion and analysis of collaborations and partnerships that have been inked between different players in this market since 2014. It includes a brief description of various types of partnership models (such as research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and others) that have been employed by stakeholders within this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to targeted protein degraders. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 13 provides information on funding instances and investments that have been made within the targeted protein degradation domain. The chapter includes details on the capital (in the form of seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings) received by companies in the period 2014-2020, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 14 features an insightful market forecast analysis, highlighting the likely growth of novel technologies designed for the development of targeted protein degraders till the year 2030, based on licensing deal structures and agreements that are expected to be signed in the foreseen future. In addition, we estimated the likely distribution of the current and forecasted opportunity across [A] different types of protein degraders (degronimids, PROTACs, SARDs / SERDs, Specific BET and DUB Inhibitors, and other inhibitors), [B] therapeutic areas (oncological disorders, neurological disorders, and other therapeutic areas), [C] route of administration (oral route, intravenous route, and other routes), and [D] key geographical regions (North America, Europe and Asia Pacific). 

Chapter 15 provides deal structure analysis, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.

Chapter 16 is a collection of interview transcripts of discussions held with key stakeholders in this market.

Chapter 17 is a summary of the overall report. It presents the key takeaways and offers our independent opinion related to the research and analysis described in the previous chapters.

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 19 is an appendix, which contains the list of companies and organizations.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Protein Homeostasis
3.3. Post Translational Protein Modifications
3.4. Ubiquitin and the Ubiquitin Proteasome System (UPS)
3.4.1. Structure and Functions of Ubiquitin
3.4.2. Overview of the UPS
3.4.2.1. Components of the UPS
3.4.2.2. Ubiquitin-based Protein Degradation Pathway

3.5. Therapeutic Applications of the UPS
3.6. Ubiquitin Enzyme Inhibitors
3.6.1. Advantages and Challenges

3.7. Overview of Targeted Protein Degradation
3.7.1. Historical Development of Protein Degraders
3.7.2. Types of Protein Degraders
3.7.2.1. Proteolysis Targeting Chimeras (PROTACs)
3.7.2.2. Other Chimeric Protein Targeting Molecules
3.7.2.2.1. Endosome Targeting Chimeras (ENDTACs)
3.7.2.2.2. Lysosome Targeting Chimeras (LYTACs)
3.7.2.2.3. Photochemically Targeted Chimeras (PHOTACs)
3.7.2.3. Epichaperome Inhibitors
3.7.2.4. Hydrophobic Tags
3.7.2.5. Immuno-modulatory Imide Drugs (IMiDs)
3.7.2.6. Molecular Glues
3.7.2.7. Protein Homeostatic Modulators
3.7.2.8. Selective Hormone Receptor Degraders (SHRDs)
3.7.2.9. Specific and Non-genetic IAP-dependent Protein Erasers (SNIPERs)
3.7.2.10. Specific Bromodomain and Extra-terminal Motif (BET) Inhibitors and Deubiquitinase (DUB) Inhibitors

3.8. Market Growth Drivers and Roadblocks
3.9. Recent Developments and Upcoming Trends

4. CURRENT MARKET LANDSCAPE: TARGET PROTEIN DEGRADATION-BASED THERAPEUTICS
4.1. Chapter Overview
4.2. Targeted Protein Degradation-based Therapeutics: Development Pipeline
4.2.1. Analysis by Type of Protein Degrader
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Target Indication
4.2.5. Analysis by Biological Target
4.2.6. Analysis by Associated Ubiquitin Ligase
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Route of Administration

4.3. Targeted Protein Degradation-based Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Protein Degrader
4.3.4. Analysis by Location of Headquarters
4.3.5. Leading Players: Analysis by Number of Drug Candidates

5. CURRENT MARKET LANDSCAPE: TARGET PROTEIN DEGRADATION ENABLING TECHNOLOGIES
5.1. Chapter Overview
5.2. Targeted Protein Degradation Enabling Technologies: List of Research Tools / Key Technology Platforms
5.2.1. Analysis by Type of Protein Degrader
5.2.2. Analysis by Number of Drugs under Development
5.3. Targeted Protein Degradation Enabling Technologies: Developer Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Developers with Late-stage Clinical Candidates
6.2.1. Radius Health
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Targeted Protein Degradation-based Product Portfolio
6.2.1.3.1. Elacestrant (RAD1901)
6.2.1.4. Recent Developments and Future Outlook

6.2.2. Celgene
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Targeted Protein Degradation-based Drug Portfolio
6.2.2.3.1. Avadomide (CC-122)
6.2.2.3.2. Iberdomide (CC-220)
6.2.2.4. Recent Developments and Future Outlook

6.2.3. Sanofi Genzyme
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Targeted Protein Degradation-based Drug Portfolio
6.2.3.3.1. SAR439869
6.2.3.4. Recent Developments and Future Outlook

6.2.4. AstraZeneca
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Targeted Protein Degradation-based Drug Portfolio
6.2.4.3.1. AZD9833
6.2.4.4. Recent Developments and Future Outlook

6.3. Developers with Preclinical / Early-stage Clinical Candidates
6.3.1. Arvinas
6.3.2. BioTheryX
6.3.3. Captor Therapeutics
6.3.4. C4 Therapeutics
6.3.5. Genentech
6.3.6. Hinova Pharmaceuticals
6.3.7. Kangpu Biopharmaceuticals
6.3.8. Kymera Therapeutics
6.3.9. Mission Therapeutics
6.3.10. Progenra
6.3.11. Zenopharm

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Clinical Trials
7.3.1. Analysis by Trial Registration Year
7.3.2. Geographical Analysis by Number of Clinical Trials
7.3.3. Geographical Analysis by Enrolled Patient Population
7.3.4. Analysis by Type of Protein Degrader
7.3.5. Analysis by Trial Phase
7.3.6. Analysis by Study Design
7.3.7. Analysis by Type of Sponsor / Collaborator
7.3.8. Most Active Players: Analysis by Number of Registered Trials
7.3.9. Analysis by Trial Focus
7.3.10. Analysis by Therapeutic Area
7.3.11. Analysis by Clinical Endpoints

8. ACADEMIC GRANTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Target Protein Degradation: Analysis of Academic Grants
8.3.1. Analysis by Year of Grant Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Funding Institute Center
8.3.4. Analysis by Support Period
8.3.5. Analysis by Funding Institute Center and Support Period
8.3.6. Analysis by Type of Grant Application
8.3.7. Analysis by Purpose of Grant Award
8.3.8. Analysis by Activity Code
8.3.9. Emerging Focus Areas (Word Cloud)
8.3.10. Analysis by Study Section Involved
8.3.11. Popular NIH Departments: Analysis by Number of Grants
8.3.12. Analysis by Type of Recipient Organization
8.3.13. Prominent Program Officers: Analysis by Number of Grants
8.3.14. Popular Recipient Organizations: Analysis by Number of Grants
8.3.15. Regional Distribution of Recipient Organizations

9. PUBLICATION ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Targeted Protein Degradation-Based Therapeutics and Technologies: Recent Publications
9.3.1. Analysis by Year of Publication
9.3.2. Analysis by Study Objective
9.3.3. Emerging Focus Areas
9.3.4. Analysis by Type of Protein Degrader
9.3.5. Analysis by Target Protein
9.3.6. Analysis by Target Enzyme
9.3.7. Analysis by Target Indication
9.3.8. Analysis by Type of Publisher
9.3.9. Leading Players: Analysis by Number of Publications
9.3.10. Leading Players: Geographical Analysis by Number of Publications
9.3.11. Key Journals: Analysis by Number of Publications

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Targeted Protein Degradation Technologies: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Application Year
10.3.3. Analysis by Geographical Location
10.3.4. Analysis by CPC Symbols
10.3.5. Emerging Focus Areas (Word Cloud)
10.3.6. Analysis by Type of Organization
10.3.7. Leading Players: Analysis by Number of Patents
10.4. Target Protein Degradation Technologies: Benchmarking Patent Analysis
10.4.1. Analysis by Patent Characteristics
10.5. Target Protein Degradation-based Technologies: Patent Valuation Analysis
10.6. Leading Patents by Number of Citations

11. KOL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Principal Investigators
11.3.1. Analysis by Designation
11.3.2. Analysis by Phase of Development and Type of Protein Degrader
11.3.3. Analysis by Therapeutic Area
11.3.4. Analysis by Type of Organization
11.3.5. Analysis by Location of Organization
11.3.6. Leading Organizations: Analysis by Number of Affiliated Principal Investigators

11.4. Prominent Key Opinion Leaders (KOLs)
11.5. KOL Benchmarking: Roots Analysis versus Third Party Scoring (ResearchGate Score)
11.6. Profiles of Most Active KOLs
11.6.1. Profile: KOL A (Barbara Ann Karmanos Cancer Center)
11.6.2. Profile: KOL B (Celgene)
11.6.3. Profile: KOL C (Feinberg School of Medicine, Northwestern University)
11.6.4. Profile: KOL D (Royal Marsden NHS Foundation Trust)
11.6.5. Profile: KOL E (Samus Therapeutics)
11.6.6. Profile: KOL F (Stanford Women Cancer Center)
11.6.7. Profile: KOL G (University of North Carolina at Chapel Hill)
11.6.8. Profile: KOL H (University of Toledo)

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Targeted Protein Degradation-based Therapeutics and Technologies: Recent Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Type of Protein Degrader
12.3.4. Analysis by Protein Degradation Technology
12.3.5. Analysis by Therapeutic Area
12.3.6. Most Active Players: Analysis by Number of Partnerships
12.3.7. Geographical Analysis
12.3.7.1. Most Active Players: Regional Analysis by Number of Partnerships
12.3.7.2. Intercontinental and Intracontinental Agreements

13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. Targeted Protein Degradation-based Therapeutics and Technologies: Recent Funding Instances
13.3.1. Analysis by Year of Investment
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Analysis by Amount Invested for Different Types of Degraders
13.3.5. Analysis by Amount Invested across Different Therapeutic Areas
13.3.6. Analysis by Amount Invested across Different Technology Platforms
13.3.7. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
13.3.8. Most Active Investors: Analysis by Participation
13.3.9. Geographical Analysis by Amount Invested
13.4. Concluding Remarks

14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Targeted Protein Degradation-based Therapeutics and Technologies: Information on Licensing Deals

14.4. Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2021-2030
14.4.1. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader
14.4.1.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2021-2030
14.4.1.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2021-2030
14.4.1.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs / SERDs, 2021-2030
14.4.1.4. Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2021-2030
14.4.1.5. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Inhibitors, 2021-2030

14.4.2. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area
14.4.2.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2021-2030
14.4.2.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, 2021-2030
14.4.2.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2021-2030

14.4.3. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration
14.4.3.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2021-2030
14.4.3.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2021-2030
14.4.3.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes of Administration, 2021-2030

14.4.4. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Geography
14.4.4.1. Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2021-2030
14.4.4.2. Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2021-2030
14.4.4.3. Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2021-2030
14.4.5. Targeted Protein Degradation-based Therapeutics and Technologies Market: Share of Key Contributing Technologies, 2021-2030

15. LICENSING DEAL STRUCTURE

16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Polyprox Therapeutics
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Laura Itzhaki, Founder and Chief Scientific Officer
16.3. Xios Therapeutics
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Louise Bergeron, Vice President
16.4. Almac
16.4.1. Company Snapshot
16.4.2. Interview Transcript: Martin Wiles, Vice President Business Development and Licensing & Gerald Gavory, Director of Biology
16.5. Ubiquigent
16.5.1. Company Snapshot
16.5.2. Interview Transcript: Jason Brown, Scientific and Business Development Director
16.6. Interview Transcript: Anonymous, Director of Oncology Research
16.7. Interview Transcript: Anonymous, Chief Scientific Officer
16.8. Mission Therapeutics
16.8.1. Company Snapshot
16.8.2. Paul Wallace, Chief Business Officer
16.9. Francis Crick Institute
16.9.1. Company Snapshot
16.9.2. Interview Transcript: Katrin Rittinger, Research Group Leader
16.10. University of Delaware
16.10.1. Company Snapshot
16.10.2. Interview Transcript: Zhihao Zhuang, Associate Professor, Department of Chemistry and Biochemistry

17. CONCLUDING REMARKS

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Important Mechanisms of Protein Surveillance
Figure 3.2 Common Types of Post-translational Modifications
Figure 3.3 Mechanism-based Analogies in Phosphorylation and Ubiquitination
Figure 3.4 Key Differences between Phosphorylation and Ubiquitination
Figure 3.5 Ubiquitin: Types of Target Proteins
Figure 3.6 Genetic Evolution of the UPS in Eukaryotes
Figure 3.7 Key Components of the UPS
Figure 3.8 Key Steps Involved in Protein Degradation via the Ubiquitin-Proteasome Pathway
Figure 3.9 Different Modes of Ubiquitination
Figure 3.10 Biological Functions of Ubiquitination
Figure 3.11 Role of UPS in Disease Development Process
Figure 3.12 Key Therapeutic Areas Targeted by UPS Modulating Drug Candidates
Figure 3.13 Key Differences Between Protein Degrader and Protein Inhibitor
Figure 3.14 Historical Evolution of Targeted Protein Degradation
Figure 3.15 Types of Protein Degraders
Figure 3.16 Mechanism of Action of PROTACs
Figure 3.17 Mechanism of Action of ENDTACs
Figure 3.18 Mechanism of Action of LYTACs
Figure 3.19 Mechanism of Action of PHOTACs
Figure 3.20 Mechanism of Action of Epichaperome Inhibitors
Figure 3.21 Mechanism of Action of Hydrophobic Tags
Figure 3.22 Mechanism of Action of IMiDs
Figure 3.23 Mechanism of Action of Molecular Glues
Figure 3.24 Mechanism of Action of Protein Homeostatic Modulators
Figure 3.25 Mechanism of Action of SHRDs
Figure 3.26 Mechanism of Action of SNIPERs
Figure 3.27 Key Growth Drivers and Roadblocks Related to Targeted Protein Degraders
Figure 4.1 Targeted Protein Degradation-based Therapeutics: Distribution by Type of Protein Degrader
Figure 4.2 Targeted Protein Degradation-based Therapeutics: Distribution by Phase of Development
Figure 4.3 Targeted Protein Degradation-based Therapeutics: Distribution by Phase of Development and Type of Protein Degrader
Figure 4.4 Targeted Protein Degradation-based Therapeutics: Distribution by Therapeutic Area
Figure 4.5 Popular Indications: Distribution by Number of Drug Candidates
Figure 4.6 Targeted Protein Degradation-based Therapeutics: Distribution by Therapeutic Area and Type of Protein Degrader
Figure 4.7 Targeted Protein Degradation-based Therapeutics: Distribution by Therapeutic Area and Phase of Development
Figure 4.8 Popular Biological Target: Distribution by Number of Drug Candidates
Figure 4.9 Popular Associated Ubiquitin Ligase: Distribution by Number of Drug Candidates
Figure 4.10 Targeted Protein Degradation-based Therapeutics: Distribution by Biological Target and Type of Protein Degrader
Figure 4.11 Targeted Protein Degradation-based Therapeutics: Distribution by Biological Target and Phase of Development
Figure 4.12 Targeted Protein Degradation-based Therapeutics: Distribution by Type of Therapy
Figure 4.13 Targeted Protein Degradation-based Therapeutics: Distribution by Route of Administration
Figure 4.14 Targeted Protein Degradation-based Therapeutics: Distribution of Industry Players by Year of Establishment
Figure 4.15 Targeted Protein Degradation-based Therapeutics: Distribution of Industry Players by Location of Headquarters
Figure 4.16 Targeted Protein Degradation-based Therapeutics: Distribution of Industry Players by Company Size
Figure 4.17 Targeted Protein Degradation-based Therapeutics: Distribution of Industry Players by Type of Protein Degrader
Figure 4.18 Targeted Protein Degradation-based Therapeutics: Geographical Distribution of Industry Players by Type of Protein Degrader
Figure 4.19 Leading Players: Distribution by Number of Drug Candidates
Figure 5.1 Targeted Protein Degradation Enabling Technologies: Distribution by Type of Protein Degrader
Figure 5.2 Targeted Protein Degradation Enabling Technologies: Distribution by Number of Drugs Under Development
Figure 5.3 Targeted Protein Degradation Enabling Technologies: Distribution of Industry Players by Year of Establishment
Figure 5.4 Targeted Protein Degradation Enabling Technologies: Distribution of Industry Players by Location of Headquarters
Figure 5.5 Targeted Protein Degradation Enabling Technologies: Distribution of Industry Players by Company Size
Figure 6.1 Celgene: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Figure 6.2 Sanofi Genzyme: Net Revenues, FY 2014 – H1 2020 (USD Million)
Figure 6.3 AstraZeneca: Net Revenues, FY 2014 – Q3 2020 (USD Billion)
Figure 7.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.2 Clinical Trials: Cumulative Distribution by Trial Registration Year, Pre-2012-2021 (till January)
Figure 7.3 Clinical Trial Analysis: Geographical Distribution of Trials
Figure 7.4 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
Figure 7.5 Clinical Trial Analysis: Distribution by Type of Protein Degrader
Figure 7.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.7 Clinical Trial Analysis: Distribution by Type of Protein Degrader and Trial Phase
Figure 7.8 Clinical Trial Analysis: Distribution by Registration Year, Type of Protein Degrader and Leading Players
Figure 7.9 Clinical Trial Analysis: Distribution by Target Indication, Type of Protein Degrader, Trial Phase and Trial Registration Year
Figure 7.10 Clinical Trial Analysis: Distribution by Study Design
Figure 7.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.12 Most Active Players: Distribution by Number of Registered Trials
Figure 7.13 Word Cloud: Popular Keywords
Figure 7.14 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.15 Clinical Trial Analysis: Benchmarking by Number of Trials across Popular Indications
Figure 7.16 Clinical Trial Analysis: Distribution by Trial Phase and Popular Indications
Figure 7.17 Clinical Trial Analysis: Benchmarking of Leading Players by Number of Trials across Key Therapeutic Indications
Figure 7.18 Clinical Trials: Most Popular Clinical Endpoints by Phase of Development
Figure 8.1 Grant Analysis: Cumulative Trend by Year of Grant Award, 2016-2020
Figure 8.2 Grant Analysis: Year-wise Distribution of Grant Amount (USD Million), 2016-2020
Figure 8.3 Grant Analysis: Distribution by Funding Institute Center
Figure 8.4 Grant Analysis: Distribution by Support Period
Figure 8.5 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 8.6 Grant Analysis: Distribution by Type of Grant Application
Figure 8.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 8.8 Grant Analysis: Distribution by Activity Code
Figure 8.9 Word Cloud: Emerging Focus Areas
Figure 8.10 Grant Analysis: Distribution by Study Section Involved
Figure 8.11 Popular NIH Departments: Distribution by Number of Grants
Figure 8.12 Grant Analysis: Distribution by Type of Recipient Organization
Figure 8.13 Prominent Program Officers: Distribution by Number of Grants
Figure 8.14 Popular Recipient Organizations: Distribution by Number of Grants
Figure 8.15 Grant Analysis: Regional Distribution of Recipient Organizations
Figure 9.1 Recent Publications: Distribution by Type of Publication
Figure 9.2 Recent Publications: Cumulative Year-wise Trend, 2017-Q3 2019
Figure 9.3 Recent Publications: Distribution by Study Objective
Figure 9.4 Recent Publications: Emerging Focus Areas
Figure 9.5 Recent Publications: Distribution by Type of Protein Degrader
Figure 9.6 Recent Publications: Distribution by Target Protein
Figure 9.7 Recent Publications: Distribution by Target Enzyme
Figure 9.8 Popular Target Indications: Distribution by Number of Publications
Figure 9.9 Recent Publications: Distribution by Type of Publisher
Figure 9.10 Most Active Players: Distribution by Number of Publications
Figure 9.11 Leading Players: Geographical Distribution by Number of Publications
Figure 9.12 Key Journals: Distribution by Number of Publications
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Distribution by Publication Year, 2018-2020
Figure 10.3 Patent Analysis: Distribution by Application Year, Pre-2017-2020
Figure 10.4 Patent Analysis: Distribution by Geographical Location
Figure 10.5 Patent Analysis: Distribution by CPC Symbols
Figure 10.6 Patent Analysis: Emerging Focus Areas
Figure 10.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Figure 10.8 Patent Analysis: Leading Industry Players
Figure 10.9 Patent Analysis: Leading Non-Industry Players
Figure 10.10 Patent Analysis: Leading Individual Assignees
Figure 10.11 Patent Analysis (Leading Industry Players): Benchmarking by Patent Characteristics (CPC Symbols)
Figure 10.12 Patent Analysis: Distribution of Patents by Age (2001-2020)
Figure 10.13 Targeted Protein Degradation Technologies: Patent Valuation
Figure 11.1 KOLs: Geographical Distribution of Principal Investigators
Figure 11.2 KOLs: Distribution by Designation
Figure 11.3 KOLs: Distribution by Phase of Development and Type of Protein Degrader
Figure 11.4 KOLs: Distribution by Therapeutic Area
Figure 11.5 KOLs: Distribution by Type of Organization
Figure 11.6 KOLs: Distribution by Location of Organization
Figure 11.7 Leading Organizations: Distribution by Number of Affiliated Principal Investigators
Figure 11.8 KOLs: Dot-Plot of Principal Investigators
Figure 11.9 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Figure 11.10 Most Prominent KOLs
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2021 (till January)
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 12.4 Partnerships and Collaborations: Distribution by Type of Protein Degrader
Figure 12.5 Partnerships and Collaborations: Year-wise Trend by Type of Protein Degrader
Figure 12.6 Partnerships and Collaborations: Distribution by Type of Protein Degrader and Type of Partnership
Figure 12.7 Popular Technology Platforms: Distribution by Number of Partnerships
Figure 12.8 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 12.9 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Figure 12.10 Partnerships and Collaborations: Distribution by Protein Degradation Technology
Figure 12.11 Most Active Players: Distribution by Number of Partnerships
Figure 12.12 Most Active Players: Geographical Distribution by Number of Partnerships
Figure 12.13 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 13.1 Funding and Investments: Distribution of Number of Funding Instances by Year of Establishment and Type of Funding, 2014-2020
Figure 13.2 Funding and Investments: Cumulative Year-wise Trend, 2014-2020
Figure 13.3 Funding and Investments: Cumulative Amount Invested by Year, 2014-2020 (USD Million)
Figure 13.4 Funding and Investments: Distribution by Type of Funding
Figure 13.5 Funding and Investments: Distribution by Amount Invested (USD Million) and Type of Funding
Figure 13.6 Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding
Figure 13.7 Funding and Investments: Summary of Investments, 2014-2020 (USD Million)
Figure 13.8 Protein Degraders: Distribution by Number of Funding Instances
Figure 13.9 Protein Degraders: Distribution by Amount Invested (USD Million)
Figure 13.10 Funding and Investments: Year-wise Distribution of Amount Invested for Different Protein Degraders, 2014-2020 (USD Million)
Figure 13.11 Popular Therapeutic Areas: Distribution by Number of Funding Instances
Figure 13.12 Popular Therapeutic Areas: Distribution by Number of Funding Instances across Different Protein Degraders
Figure 13.13 Popular Therapeutic Areas: Distribution by Amount Invested (USD Million)
Figure 13.14 Popular Technology Platforms: Distribution by Amount Invested (USD Million)
Figure 13.15 Most Active Players: Distribution by Number of Funding Instances
Figure 13.16 Most Active Players: Distribution by Capital Amount Raised (USD Million)
Figure 13.17 Most Active Investors: Distribution by Number of Funding Instances
Figure 13.18 Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Figure 13.19 Funding and Investment Summary
Figure 14.1 Licensing Agreements: Distribution of Financial Components
Figure 14.2 Targeted Protein Degradation-based Therapeutics and Technologies: Information on Licensing Deals
Figure 14.3 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2021-2030 (USD Million)
Figure 14.4 Targeted Protein Degradation-based Therapeutics and Technologies Market by Upfront Payments, till 2030 (USD Million)
Figure 14.5 Targeted Protein Degradation-based Therapeutics and Technologies Market by Milestone Payments, till 2030 (USD Million)
Figure 14.6 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader, 2021 and 2030
Figure 14.7 Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2021-2030 (USD Million)
Figure 14.8 Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2021-2030 (USD Million)
Figure 14.9 Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs / SERDs, 2021-2030 (USD Million)
Figure 14.10 Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2021-2030 (USD Million)
Figure 14.11 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area, 2021 and 2030
Figure 14.12 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2021-2030 (USD Million)
Figure 14.13 Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, 2021-2030 (USD Million)
Figure 14.14 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2021-2030 (USD Million)
Figure 14.15 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration, 2021 and 2030
Figure 14.16 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2021-2030 (USD Million)
Figure 14.17 Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2021-2030 (USD Million)
Figure 14.18 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes of Administration, 2021-2030 (USD Million)
Figure 14.19 Targeted Protein Degradation-based Therapeutics and Technologies Market: Regional Distribution, 2021 and 2030
Figure 14.20 Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2021-2030 (USD Million)
Figure 14.21 Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2021-2030 (USD Million)
Figure 14.22 Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.23 Targeted Protein Degradation-based Therapeutics and Technologies Market for Key Contributing Technologies, 2021-2030 (USD Million)
Figure 17.1 Concluding Remarks: Current Market Landscape
Figure 17.2 Concluding Remarks: Clinical Trial Analysis
Figure 17.3 Concluding Remarks: Academic Grant Analysis
Figure 17.4 Concluding Remarks: Publication Analysis
Figure 17.5 Concluding Remarks: Patent Analysis
Figure 17.6 Concluding Remarks: Partnerships and Collaborations
Figure 17.7 Concluding Remarks: Funding Analysis
Figure 17.8 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Structural Classification of Ubiquitin
Table 4.1 Targeted Protein Degradation-based Therapeutics: Development Pipeline
Table 4.2 Targeted Protein Degradation-based Therapeutics: Information on Therapeutic Area and Phase of Development
Table 4.3 Targeted Protein Degradation-based Therapeutics: Information on Type of Protein Degrader
Table 4.3 Targeted Protein Degradation-based Therapeutics: Information on Target Enzyme, Target Protein, Signaling Pathway, Type of Therapy and Route of Administration
Table 4.4 Targeted Protein Degradation-based Therapeutics: Information on Marketed First Generation Protein Degraders
Table 4.5 Targeted Protein Degradation-based Therapeutics: Developer Landscape
Table 5.1 Targeted Protein Degradation Enabling Technologies: Information on Research Tools / Key Technology Platforms
Table 5.2 Targeted Protein Degradation Enabling Technologies: Developer Landscape
Table 6.1 Radius Health: Key Highlights
Table 6.2 Drug Profile: Elacestrant (RAD1901)
Table 6.3 Radius Health: Recent Developments and Future Outlook
Table 6.4 Celgene: Key Highlights
Table 6.5 Drug Profile: Avadomide (CC-122)
Table 6.6 Drug Profile: Iberdomide (CC-220)
Table 6.7 Celgene: Recent Developments and Future Outlook
Table 6.8 Sanofi Genzyme: Key Highlights
Table 6.9 Drug profile: SAR439869
Table 6.10 Sanofi Genzyme: Recent Developments and Future Outlook
Table 6.11 AstraZeneca: Key Highlights
Table 6.12 Drug profile: AZD9833
Table 6.13 AstraZeneca: Recent Developments and Future Outlook
Table 6.14 Arvinas: Key Highlights
Table 6.15 BioTheryX: Key Highlights
Table 6.16 Captor Therapeutics: Key Highlights
Table 6.17 C4 Therapeutics: Key Highlights
Table 6.18 Genentech: Key Highlights
Table 6.19 Hinova Pharmaceuticals: Key Highlights
Table 6.20 Kangpu Biopharmaceuticals: Key Highlights
Table 6.21 Kymera Therapeutics: Key Highlights
Table 6.22 Mission Therapeutics: Key Highlights
Table 6.23 Progenra: Key Highlights
Table 6.24 Zenopharm: Key Highlights
Table 9.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Recent Publications, 2017 - Q3 2019
Table 11.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Principal Investigators
Table 11.2 KOLs: Roots Analysis Proprietary Scoring System
Table 11.3 Profile: KOL A (Barbara Ann Karmanos Cancer Center)
Table 11.4 Profile: KOL B (Celgene)
Table 11.5 Profile: KOL C (Feinberg School of Medicine, Northwestern University)
Table 11.6 Profile: KOL D (Royal Marsden NHS Foundation Trust)
Table 11.7 Profile: KOL E (Samus Therapeutics)
Table 11.8 Profile: KOL F (Stanford Women Cancer Center)
Table 11.9 Profile: KOL G (University of North Carolina at Chapel Hill)
Table 11.10 Profile: KOL H (University of Toledo)
Table 12.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Partnerships, 2014-2021 (till January)
Table 13.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Funding Instances, 2014-2020
Table 13.2 Targeted Protein Degradation-based Therapeutics and Technologies: Summary of Investments
Table 16.1 Polyprox Therapeutics: Company Snapshot
Table 16.2 Xios Therapeutics: Company Snapshot
Table 16.3 Almac: Company Snapshot
Table 16.4 Ubiquigent: Company Snapshot
Table 16.5 Mission Therapeutics: Company Snapshot
Table 16.5 Francis Crick Institute: Company Snapshot
Table 16.6 University of Delaware: Company Snapshot
Table 17.1 Targeted Protein Degradation-based Therapeutics: Distribution by Type of Protein Degrader
Table 17.2 Targeted Protein Degradation-based Therapeutics: Distribution by Phase of Development
Table 17.3 Targeted Protein Degradation-based Therapeutics: Distribution by Phase of Development and Type of Protein Degrader
Table 17.4 Targeted Protein Degradation-based Therapeutics: Distribution by Therapeutic Area
Table 17.5 Popular Indications: Distribution by Number of Drug Candidates
Table 17.6 Targeted Protein Degradation-based Therapeutics: Distribution by Therapeutic Area and Type of Protein Degrader
Table 17.7 Targeted Protein Degradation-based Therapeutics: Distribution by Therapeutic Area and Phase of Development
Table 17.8 Popular Biological Target: Distribution by Number of Drug Candidates
Table 17.9 Popular Associated Ubiquitin Ligase: Distribution by Number of Drug Candidates
Table 17.10 Targeted Protein Degradation-based Therapeutics: Distribution by Biological Target and Type of Protein Degrader
Table 17.11 Targeted Protein Degradation-based Therapeutics: Distribution by Biological Target and Phase of Development
Table 17.12 Targeted Protein Degradation-based Therapeutics: Distribution by Type of Therapy
Table 17.13 Targeted Protein Degradation-based Therapeutics: Distribution by Route of Administration
Table 17.14 Targeted Protein Degradation-based Therapeutics: Distribution of Industry Players by Year of Establishment
Table 17.15 Targeted Protein Degradation-based Therapeutics: Distribution of Industry Players by Location of Headquarters
Table 17.16 Targeted Protein Degradation-based Therapeutics: Distribution of Industry Players by Company Size
Table 17.17 Targeted Protein Degradation-based Therapeutics: Distribution of Industry Players by Type of Protein Degrader
Table 17.18 Targeted Protein Degradation-based Therapeutics: Geographical Distribution of Industry Players by Type of Protein Degrader
Table 17.19 Leading Players: Distribution by Number of Drug Candidates
Table 17.20 Targeted Protein Degradation Enabling Technologies: Distribution by Type of Protein Degrader
Table 17.21 Targeted Protein Degradation Enabling Technologies: Distribution by Number of Drugs Under Development
Table 17.22 Targeted Protein Degradation Enabling Technologies: Distribution of Industry Players by Year of Establishment
Table 17.23 Targeted Protein Degradation Enabling Technologies: Distribution of Industry Players by Location of Headquarters
Table 17.24 Targeted Protein Degradation Enabling Technologies: Distribution of Industry Players by Company Size
Table 17.25 Celgene: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Table 17.26 Sanofi Genzyme: Net Revenues, FY 2014 – H1 2020 (USD Million)
Table 17.27 AstraZeneca: Net Revenues, FY 2014 – Q3 2020 (USD Billion)
Table 17.28 Clinical Trial Analysis: Distribution by Trial Status
Table 17.29 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2012-2021 (till January)
Table 17.30 Clinical Trial Analysis: Geographical Distribution of Trials
Table 17.31 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
Table 17.32 Clinical Trial Analysis: Distribution by Type of Protein Degrader
Table 17.33 Clinical Trial Analysis: Distribution by Trial Phase
Table 17.34 Clinical Trial Analysis: Distribution by Type of Protein Degrader and Trial Phase
Table 17.35 Clinical Trial Analysis: Distribution by Registration Year, Type of Protein Degrader and Leading Players
Table 17.36 Clinical Trial Analysis: Distribution by Target Indication, Type of Protein Degrader, Trial Phase and Trial Registration Year
Table 17.37 Clinical Trial Analysis: Distribution by Study Design
Table 17.38 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 17.39 Most Active Players: Distribution by Number of Registered Trials
Table 17.40 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 17.41 Clinical Trial Analysis: Benchmarking by Number of Trials across Popular Indications
Table 17.42 Clinical Trial Analysis: Distribution by Trial Phase and Popular Indications
Table 17.43 Clinical Trial Analysis: Benchmarking of Leading Players by Number of Trials across Key Therapeutic Indications
Table 17.44 Clinical Trials: Most Popular Clinical Endpoints by Phase of Development
Table 17.45 Grant Analysis: Cumulative Trend by Year of Grant Award, 2017-2020
Table 17.46 Grant Analysis: Year-wise Distribution of Grant Amount (USD Million), 2017-2020
Table 17.47 Grant Analysis: Distribution by Funding Institute Center
Table 17.48 Grant Analysis: Distribution by Support Period
Table 17.49 Grant Analysis: Distribution by Funding Institute Center and Support Period
Table 17.50 Grant Analysis: Distribution by Type of Grant Application
Table 17.51 Grant Analysis: Distribution by Purpose of Grant Award
Table 17.52 Grant Analysis: Distribution by Activity Code
Table 17.53 Grant Analysis: Distribution by Study Section Involved
Table 17.54 Popular NIH Departments: Distribution by Number of Grants
Table 17.55 Grant Analysis: Distribution by Type of Recipient Organization
Table 17.56 Prominent Program Officers: Distribution by Number of Grants
Table 17.57 Popular Recipient Organizations: Distribution by Number of Grants
Table 17.58 Grant Analysis: Regional Distribution of Recipient Organizations
Table 17.59 Recent Publications: Distribution by Type of Publication
Table 17.60 Recent Publications: Cumulative Year-wise Trend, 2017-Q3 2019
Table 17.61 Recent Publications: Distribution by Study Objective
Table 17.62 Recent Publications: Emerging Focus Areas
Table 17.63 Recent Publications: Distribution by Type of Protein Degrader
Table 17.64 Recent Publications: Distribution by Target Protein
Table 17.65 Recent Publications: Distribution by Target Enzyme
Table 17.66 Popular Target Indications: Distribution by Number of Publications
Table 17.67 Recent Publications: Distribution by Type of Publisher
Table 17.68 Most Active Players: Distribution by Number of Publications
Table 17.69 Leading Players: Geographical Distribution by Number of Publications
Table 17.70 Key Journals: Distribution by Number of Publications
Table 17.71 Patent Analysis: Distribution by Type of Patent
Table 17.72 Patent Analysis: Cumulative Distribution by Publication Year, 2018-2020
Table 17.73 Patent Analysis: Distribution by Application Year, Pre-2017-2020
Table 17.74 Patent Analysis: Distribution by Geographical Location
Table 17.75 Patent Analysis: Distribution by CPC Symbols
Table 17.76 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Table 17.77 Patent Analysis: Leading Industry Players
Table 17.78 Patent Analysis: Leading Non-Industry Players
Table 17.79 Patent Analysis: Leading Individual Assignees
Table 17.80 Patent Analysis (Leading Industry Players): Benchmarking by Patent Characteristics (CPC Symbols)
Table 17.81 Patent Analysis: Distribution of Patents by Age (2001-2020)
Table 17.82 Targeted Protein Degradation Technologies: Patent Valuation
Table 17.83 KOLs: Geographical Distribution of Principal Investigators
Table 17.84 KOLs: Distribution by Designation
Table 17.85 KOLs: Distribution by Phase of Development and Type of Protein Degrader
Table 17.86 KOLs: Distribution by Therapeutic Area
Table 17.87 KOLs: Distribution by Type of Organization
Table 17.88 KOLs: Distribution by Location of Organization
Table 17.89 Leading Organizations: Distribution by Number of Affiliated Principal Investigators
Table 17.90 KOLs: Dot-Plot of Principal Investigators
Table 17.91 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Table 17.92 Most Prominent KOLs
Table 17.93 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2021 (till January)
Table 17.94 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.95 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 17.96 Partnerships and Collaborations: Distribution by Type of Protein Degrader
Table 17.97 Partnerships and Collaborations: Year-wise Trend by Type of Protein Degrader
Table 17.98 Partnerships and Collaborations: Distribution by Type of Protein Degrader and Type of Partnership
Table 17.99 Popular Technology Platforms: Distribution by Number of Partnerships
Table 17.100 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 17.101 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Table 17.102 Partnerships and Collaborations: Distribution by Protein Degradation Technology
Table 17.103 Most Active Players: Distribution by Number of Partnerships
Table 17.104 Most Active Players: Geographical Distribution by Number of Partnerships
Table 17.105 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 17.106 Funding and Investments: Distribution by Year of Establishment and Type of Funding, 2014-2020
Table 17.107 Funding and Investments: Cumulative Year-wise Trend, 2014-2020
Table 17.108 Funding and Investments: Cumulative Amount Invested by Year, 2014-2020 (USD Million)
Table 17.109 Funding and Investments: Distribution by Type of Funding
Table 17.110 Funding and Investments: Distribution by Amount Invested (USD Million) and Type of Funding
Table 17.111 Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding
Table 17.112 Funding and Investments: Summary of Investments, 2014-2020 (USD Million)
Table 17.113 Protein Degraders: Distribution by Number of Funding Instances
Table 17.114 Protein Degraders: Distribution by Amount Invested (USD Million)
Table 17.115 Funding and Investments: Year-wise Distribution of Amount Invested for Different Protein Degraders, 2014-2020 (USD Million)
Table 17.116 Popular Therapeutic Areas: Distribution by Number of Funding Instances
Table 17.117 Popular Therapeutic Areas: Distribution by Number of Funding Instances across Different Protein Degraders
Table 17.118 Popular Therapeutic Areas: Distribution by Amount Invested (USD Million)
Table 17.119 Popular Technology Platforms: Distribution by Amount Invested (USD Million)
Table 17.120 Most Active Players: Distribution by Number of Funding Instances
Table 17.121 Most Active Players: Distribution by Capital Amount Raised (USD Million)
Table 17.122 Most Active Investors: Distribution by Number of Funding Instances
Table 17.123 Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Table 17.124 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2021-2030 (USD Million)
Table 17.125 Targeted Protein Degradation-based Therapeutics and Technologies Market by Upfront Payments, till 2030 (USD Million)
Table 17.126 Targeted Protein Degradation-based Therapeutics and Technologies Market by Milestone Payments, till 2030 (USD Million)
Table 17.127 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader, 2021 and 2030
Table 17.128 Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2021-2030 (USD Million)
Table 17.129 Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2021-2030 (USD Million)
Table 17.130 Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs / SERDs, 2021-2030 (USD Million)
Table 17.131 Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2021-2030 (USD Million)
Table 17.132 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area, 2021 and 2030
Table 17.133 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2021-2030 (USD Million)
Table 17.134 Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, 2021-2030 (USD Million)
Table 17.135 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2021-2030 (USD Million)
Table 17.136 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration, 2021 and 2030
Table 17.137 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2021-2030 (USD Million)
Table 17.138 Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2021-2030 (USD Million)
Table 17.139 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes of Administration, 2021-2030 (USD Million)
Table 17.140 Targeted Protein Degradation-based Therapeutics and Technologies Market: Regional Distribution, 2021 and 2030
Table 17.141 Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2021-2030 (USD Million)
Table 17.142 Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2021-2030 (USD Million)
Table 17.143 Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2021-2030 (USD Million)

List Of Companies

The following companies / organizations have been mentioned in this report.

  1. 6 Dimensions Capital
  2. AbbVie
  3. Abingworth
  4. Advantech Capital
  5. Advent Life Sciences
  6. AIHC Capital
  7. Aisling Capital
  8. AJU IB Investment
  9. Alexandria Venture Investments
  10. Alfred Berg
  11. Almac Discovery
  12. Alpha Stem Cell Clinic
  13. Altitude Life Science Ventures
  14. AM Capital
  15. Amgen
  16. Amgen Ventures
  17. Amphista Therapeutics
  18. Amzak Health
  19. ARCH Venture Partners
  20. Arpeggio Biosciences
  21. Arvinas
  22. AstraZeneca
  23. Atlas Venture
  24. Avista Pharma Solutions
  25. Bain Capital Life Sciences
  26. Bayer
  27. Beactica
  28. BeiGene
  29. Bellco Capital
  30. Bessemer Venture Partners
  31. Beth Israel Deaconess Medical Center
  32. BeyondSpring Pharmaceuticals
  33. Biogen
  34. BioMotiv
  35. BioRap Technologies
  36. Biotech Investment Fund
  37. BioTheryX
  38. BlackRock
  39. Boehringer Ingelheim
  40. Borun Investment
  41. Brigham And Women's Hospital
  42. Bristol Myers Squibb
  43. BVF Partners
  44. C4 Therapeutics
  45. Calico
  46. California Institute for Regenerative Medicine
  47. Cambridge Enterprise
  48. Cambridge Innovation Capital
  49. Cambridge Stem Cell Institute
  50. Cancer Prevention & Research Institute of Texas
  51. Cancer Research Technology
  52. Cancer Research UK Manchester Institute
  53. Capital Pathology Bega
  54. Captor Therapeutics
  55. Cardinal Partners
  56. Carmot Therapeutics
  57. Casdin Capital
  58. CCB Medical Devices
  59. Cedilla Therapeutics
  60. Celgene
  61. CellCentric
  62. Centre for Clinical Hematology, Queen Elizabeth Hospital
  63. Chengdu Dingjian
  64. Children's Hospital of Philadelphia, University of Pennsylvania
  65. China Construction Bank
  66. Chugai Pharmaceuticals
  67. ClinAssess
  68. CMB International Capital
  69. Cobro Ventures
  70. Cormorant Asset Management
  71. Cosmo Bio
  72. Covance
  73. Cowen
  74. Cowen Private Investments
  75. Crede Capital Group
  76. Cullgen
  77. CVC Capital Partners
  78. Cyclofluidic
  79. Dana-Farber Cancer Institute
  80. DCVC
  81. Deerfield Management
  82. Dialectic Therapeutics
  83. DMS Group
  84. Dorian Therapeutics
  85. DROIA Ventures
  86. Duke University
  87. Dyee Capital
  88. E Fund Management
  89. EcoR1 Capital
  90. EG Capital
  91. Eisai
  92. Elan Science One
  93. Eli Lilly
  94. Emeriti Bio
  95. EMN Research Italy
  96. Eriksam Invest Aktiebolag
  97. Eshelman Ventures
  98. Eternal Thrive
  99. European Investment Fund
  100. European Myeloma Network
  101. European Regional Development Fund
  102. Eventide Asset Management
  103. Evotec
  104. Farallon Capital Management
  105. Fidelity Biosciences
  106. FIMECS
  107. Five Elements Bio-technology
  108. Fjärde AP-fonden
  109. Foresite Capital
  110. FORMA Therapeutics
  111. Fosun
  112. Franklin Templeton Investments
  113. Fred Hutchinson Cancer Research Center
  114. Frontier Medicines
  115. G1 Therapeutics
  116. Genentech
  117. GF Xinde Investment Management
  118. Gilead Sciences
  119. GL Ventures
  120. Gladiator
  121. GlaxoSmithKline
  122. GMIHO Medizinische Innovation -Hämatologie und Onkologie
  123. GNI Group
  124. GV
  125. GVK Biosciences
  126. H. Lee Moffitt Cancer Center and Research Institute
  127. Haisco Pharmaceutical
  128. Handelsbanken Fonder
  129. Harvard Medical School
  130. Hatteras Venture Partners
  131. HBM Healthcare Investments
  132. Healt Data Specialists
  133. HealthCap
  134. HealthCare Ventures
  135. Hermed Alpha
  136. HighLight Capital
  137. Hinova Pharmaceuticals
  138. HitGen
  139. Honghui Capital
  140. Horizon Discovery
  141. Horizons Venture
  142. Huarong Rongde Asset Management
  143. Hybrigenics Pharma
  144. IGM Biosciences
  145. ImmunoLogik
  146. Imperial Innovations
  147. INIM Pharma
  148. Innovate UK
  149. Institute of Cancer And Genomic Science
  150. Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
  151. InventisBio
  152. Invus
  153. IP Group
  154. Janchor Partners
  155. Janpix
  156. Janssen Research & Development
  157. Janus Henderson Investors
  158. Jiangsu HengRui Medicine
  159. Kai Kuang Pharmaceutical
  160. Kangpu Biopharmaceuticals
  161. Kronos Bio
  162. Kymera Therapeutics
  163. Kyoto University Innovation Capital
  164. Lang Sheng Investment Group
  165. Legend Biotech
  166. Lenovo Star
  167. LifeArc
  168. Lilly Asia Ventures
  169. Lilly Ventures
  170. Longwood Fund
  171. Loxo Oncology
  172. Lumira Capital
  173. Lycia Therapeutics
  174. M Ventures
  175. M.D. Anderson Cancer Center
  176. Macroceutics
  177. Massachusetts General Hospital
  178. Matrix Capital
  179. Matrix Partner China
  180. McGill University
  181. MD Anderson Cancer Center
  182. MedImmune Ventures
  183. Medivir
  184. Memorial Sloan Kettering Cancer Center
  185. Menarini Group
  186. Merck
  187. Mirae Asset Capital
  188. Mission Therapeutics
  189. Monte Rosa Therapeutics
  190. Moonstone Investments
  191. Morningside Venture Investments
  192. Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute
  193. Mountain Group Partners
  194. MPM Capital
  195. MRL Ventures Fund
  196. Mubadala Ventures
  197. Nanjing General Hospital of People's Liberation Army
  198. Nanologica
  199. National Cancer Institute
  200. National Centre for Research and Development
  201. National Institute of Genetics
  202. National Institute of Health
  203. Neotribe Ventures
  204. New Enterprise Associates
  205. Nextech Invest
  206. Nordic Cross
  207. Novartis
  208. Novartis Institutes for BioMedical Research
  209. Novartis Venture Fund
  210. Nuevolution
  211. Nurix Therapeutics
  212. Nyenburgh Investment Partners
  213. Oerth Bio
  214. Ohio State University
  215. Omega Funds
  216. Oncternal Therapeutics
  217. OrbiMed
  218. Oriental Securities Capital
  219. Orionis Biosciences
  220. Oxford Finance
  221. Parexel
  222. Penn Medicine Abramson Cancer Center
  223. Perceptive Advisors
  224. Pfizer
  225. Pfizer Ventures
  226. Pin Therapeutics
  227. Plexium
  228. Polaris Partners
  229. PolyProx Therapeutics
  230. Profacgen
  231. Progenra
  232. Promega
  233. Prostate Cancer Foundation
  234. Proteostasis Therapeutics
  235. Providence Investment
  236. Proxygen
  237. Pudong Innotek
  238. Qiming Venture Partners
  239. Queen's University
  240. Quotient Sciences
  241. RA Capital
  242. Radius Health
  243. Redmile Group
  244. Roche
  245. Roche Venture Fund
  246. Rock Springs Capital
  247. Rockefeller University
  248. Roivant Sciences
  249. Roswell Park Cancer Institute
  250. RT Capital
  251. Samus Therapeutics
  252. Sanofi Genzyme
  253. Sanofi Ventures
  254. Schroder Adveq
  255. Scottish Investment Bank
  256. Seed Therapeutics
  257. Sequoia Capital China
  258. Seragon Pharmaceuticals
  259. Servier
  260. Shanghai Free Trade Zoon Equity Fund
  261. Shanghai Furong Investment
  262. Shenzhen Guozhong Venture Capital
  263. Shenzhen Investment Holdings
  264. Shenzhen Sangel Zhichuang Investment
  265. SinoPharm Capital
  266. Sitryx Therapeutics
  267. SK Holdings
  268. Sofinnova Partners
  269. Solar Capital
  270. Songhe Capital
  271. Sosei Heptares
  272. SR One
  273. St. Antonius Hospital
  274. Stanford University
  275. Sun Pharma Advanced Research Company
  276. Surveyor Capital
  277. Suzhou Pioneer Pharmaceutical
  278. SV Health Investors
  279. SV Torch
  280. Swedbank Robur
  281. Sygnature Discovery
  282. Takeda Pharmaceutical
  283. Tavistock Life Sciences
  284. Tavros Therapeutics
  285. Tetralogic Pharmaceuticals
  286. The Chinese University of Hong Kong
  287. The Column Group
  288. The Institute of Cancer Research
  289. The Kraft Group
  290. The Michael J. Fox Foundation
  291. The Netherlands Cancer Institute
  292. The Silverstein Foundation for Parkinson’s with GBA
  293. Third Rock Ventures
  294. Tigermed
  295. Tokalas
  296. Trilo Therapeutics
  297. Trinitas Capital
  298. Tybourne Capital Management
  299. UbiQ Bio
  300. Ubiquigent
  301. Ubix Therapeutics
  302. UCLA Jonsson Comprehensive Cancer Center
  303. Unionen
  304. University Health Network
  305. University Hospital Erlangen
  306. University Hospital of Würzburg
  307. University of California, Berkeley
  308. University of California, San Francisco
  309. University of Dundee
  310. University of Florida
  311. University of Illinois
  312. University of Liverpool
  313. University of Maryland, Baltimore
  314. University of Michigan
  315. University of Oxford
  316. University of Southern Denmark
  317. University of Tennessee Research Foundation
  318. University of Washington
  319. Vagelos College of Physicians and Surgeons
  320. Versant Ventures
  321. Vertex Pharmaceuticals
  322. Vicore Pharma
  323. Vida Ventures
  324. Viking Global Investors
  325. Vividion Therapeutics
  326. VU University Medical Center
  327. Washington University School of Medicine
  328. Weill Medical College of Cornell University
  329. Wellington Management
  330. Woodford Patient Capital Trust
  331. WrocÅ‚aw Research Centre EIT+ 
  332. X-Chem
  333. Xios Therapeutics
  334. Yale University
  335. Yissum
  336. Yuanhe Holdings
  337. Yuansheng Venture Capital
  338. Zenopharm
  339. Zentalis Pharmaceuticals
  340. Zentera
  341. Zhuhai Huajin Capital

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com